211 related articles for article (PubMed ID: 27768168)
1. Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden.
Loeb S; Folkvaljon Y; Curnyn C; Robinson D; Bratt O; Stattin P
JAMA Oncol; 2017 Oct; 3(10):1393-1398. PubMed ID: 27768168
[TBL] [Abstract][Full Text] [Related]
2. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S; Berglund A; Stattin P
J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
[TBL] [Abstract][Full Text] [Related]
3. Five-year nationwide follow-up study of active surveillance for prostate cancer.
Loeb S; Folkvaljon Y; Makarov DV; Bratt O; Bill-Axelson A; Stattin P
Eur Urol; 2015 Feb; 67(2):233-8. PubMed ID: 24993868
[TBL] [Abstract][Full Text] [Related]
4. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
5. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
[TBL] [Abstract][Full Text] [Related]
6. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
[TBL] [Abstract][Full Text] [Related]
7. Gleason inflation 1998-2011: a registry study of 97,168 men.
Danneman D; Drevin L; Robinson D; Stattin P; Egevad L
BJU Int; 2015 Feb; 115(2):248-55. PubMed ID: 24552193
[TBL] [Abstract][Full Text] [Related]
8. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
10. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.
Godtman RA; Holmberg E; Khatami A; Stranne J; Hugosson J
Eur Urol; 2013 Jan; 63(1):101-7. PubMed ID: 22980443
[TBL] [Abstract][Full Text] [Related]
11. The impact of pretreatment PSA on risk stratification in men with Gleason 6 prostate cancer: Implications for active surveillance.
Monfared S; Fleishman A; Korets R; Chang P; Wagner A; Bubley G; Kaplan I; Olumi AF; Gershman B
Urol Oncol; 2021 Nov; 39(11):783.e21-783.e30. PubMed ID: 33992521
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
Rider JR; Sandin F; Andrén O; Wiklund P; Hugosson J; Stattin P
Eur Urol; 2013 Jan; 63(1):88-96. PubMed ID: 22902040
[TBL] [Abstract][Full Text] [Related]
13. Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer.
Lonergan PE; Washington SL; Cowan JE; Zhao S; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
J Urol; 2020 Dec; 204(6):1216-1221. PubMed ID: 32519915
[TBL] [Abstract][Full Text] [Related]
14. Active Surveillance for Men with Intermediate Risk Prostate Cancer.
Agrawal V; Ma X; Hu JC; Barbieri CE; Nagar H
J Urol; 2021 Jan; 205(1):115-121. PubMed ID: 32658588
[TBL] [Abstract][Full Text] [Related]
15. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
[TBL] [Abstract][Full Text] [Related]
16. Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists.
Kim SP; Shah ND; Meropol NJ; Tilburt JC; Nguyen PL; Yu JB; Abouassaly R; Kim A; Gross CP
Eur Urol Oncol; 2019 Mar; 2(2):189-195. PubMed ID: 31017095
[TBL] [Abstract][Full Text] [Related]
17. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study.
Stattin P; Holmberg E; Johansson JE; Holmberg L; Adolfsson J; Hugosson J;
J Natl Cancer Inst; 2010 Jul; 102(13):950-8. PubMed ID: 20562373
[TBL] [Abstract][Full Text] [Related]
18. Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer.
Mahal BA; Aizer AA; Efstathiou JA; Nguyen PL
Cancer; 2016 Jan; 122(1):78-83. PubMed ID: 26371600
[TBL] [Abstract][Full Text] [Related]
19. Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy: Defining a Favorable Intermediate-Risk Group.
Patel HD; Tosoian JJ; Carter HB; Epstein JI
JAMA Oncol; 2018 Jan; 4(1):89-92. PubMed ID: 28715578
[TBL] [Abstract][Full Text] [Related]
20. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
Maggi M; Cowan JE; Fasulo V; Washington SL; Lonergan PE; Sciarra A; Nguyen HG; Carroll PR
J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]